FDA recall D-0418-2025 · initiated Mar 5, 2025
May cause temporary or medically reversible harm; low probability of serious harm.
cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots.